<DOC>
	<DOCNO>NCT02516579</DOCNO>
	<brief_summary>In context Risk Management Plan ( RMP ) , request Addmedica EMEA , collect information long-term safety Siklos® ( hydroxycarbamide ) use current practice prevention symptomatic vaso-occlusive complication patient Sickle Cell Disease .</brief_summary>
	<brief_title>European Sickle Cell Disease Cohort - Hydroxyurea</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>Male female ambulatory patient , age 2 year ( child , adolescent adult ) With symptomatic sickle cell syndrome Justifying treatment Siklos® accord product indication Having inform study initiate physician consent participate cohort .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>